Q32 Bio (NASDAQ:QTTB) Insider Shelia Violette Sells 2,815 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) insider Shelia Violette sold 2,815 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $12,695.65. Following the transaction, the insider owned 55,569 shares in the company, valued at $250,616.19. This represents a 4.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Q32 Bio Price Performance

NASDAQ:QTTB traded down $0.20 during trading hours on Friday, reaching $4.56. The company’s stock had a trading volume of 203,990 shares, compared to its average volume of 149,267. The company has a market cap of $56.11 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. Q32 Bio Inc. has a one year low of $1.35 and a one year high of $6.37. The business’s 50-day moving average is $3.81 and its 200-day moving average is $2.90.

Institutional Trading of Q32 Bio

A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Q32 Bio in the 4th quarter valued at $68,000. Opaleye Management Inc. acquired a new position in Q32 Bio in the fourth quarter valued at about $708,000. ADAR1 Capital Management LLC acquired a new stake in shares of Q32 Bio during the fourth quarter worth approximately $66,000. Jane Street Group LLC acquired a new position in shares of Q32 Bio in the 4th quarter worth approximately $84,000. Finally, HRT Financial LP grew its position in Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after acquiring an additional 9,862 shares during the last quarter. 31.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on QTTB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. HC Wainwright began coverage on shares of Q32 Bio in a research note on Wednesday. They issued a “buy” rating and a $13.00 target price on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Q32 Bio has an average rating of “Hold” and a consensus price target of $14.00.

Key Stories Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.